Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amplia TherapeuticsASX:ATX 27 3-Year EBITDA Growth Rate is 18.90% as of Mar. 2026, which is 4% above its 10-year median of 18.15. GuruFocus rates ASX:ATX with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 1,132 Biotechnology companies, Amplia Therapeutics ranks better than 54.77% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 18.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 25.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amplia Therapeutics was 51.80% per year. The lowest was -25.50% per year. And the median was 18.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Amplia Therapeutics 3-Year EBITDA Growth Rate Related Terms
ASX:ATX vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Amplia Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amplia Therapeutics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Amplia Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 18.90% mean?
Amplia Therapeutics (ASX:ATX) has a 3-Year EBITDA Growth Rate of 18.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amplia Therapeutics and its competitors. This is near median its historical median of 18.15. According to the industry distribution chart, Amplia Therapeutics ranks #512 out of 1132 companies in the Biotechnology industry, placing it in the top 45.2%.
Is Amplia Therapeutics' 3-Year EBITDA Growth Rate too high?
Amplia Therapeutics' current 3-Year EBITDA Growth Rate of 18.90% is near median its 10-year median of 18.15. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Amplia Therapeutics' value of 18.90% is 27.3% above this industry median. Based on the distribution chart, Amplia Therapeutics ranks #512 out of 1132 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Amplia Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Amplia Therapeutics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Amplia Therapeutics ranks #512 out of 1132 companies for 3-Year EBITDA Growth Rate. This puts Amplia Therapeutics in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.85. Amplia Therapeutics' value of 18.90% is 27.3% above this benchmark. While the company's 10-year median is 18.15 vs. the industry median of 14.85, Amplia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,132 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amplia Therapeutics's current 3-Year EBITDA Growth Rate of 18.90% is 27.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amplia Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amplia Therapeutics's current 3-Year EBITDA Growth Rate is 18.90%, which is near median its own 10-year median of 18.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amplia Therapeutics stock overvalued right now?
Amplia Therapeutics (ASX:ATX) has a current 3-Year EBITDA Growth Rate of 18.90%. The current 3-Year EBITDA Growth Rate is 18.90%, which is near median its 10-year median of 18.15 and 27.3% above the Biotechnology industry median of 14.85. Amplia Therapeutics' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current 3-Year EBITDA Growth Rate is 18.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
27GF Score
Get the complete analysis for ASX:ATX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ATX has been successfully added to your 
